An NLRP3 inflammasome inhibitor inhibits the release of IL-1B and decreases caspase-1 levels in LPS-stimulated J774A 1 murine macrophages HMDMs and primary human blood neutrophils selective for NLRP3 over NLRP4 and AIM2 inflammasomes at concentrations up to 100 M inhibits ASC oligomerization and NLRP3 association with caspase-1 and ASC in LPS- and nigericin-stimulated J774A 1 cells reduces MPO CXCL1 and IL-6 levels in peritoneal fluid as well as IL-1B levels in liver lung spleen and skeletal muscle in a mouse model of LPS-induced systemic inflammation increases markers of oxidative metabolism in muscle in mouse model of LPS-induced systemic inflammation reduces IL-1B release in blood monocytes isolated from patients with CAPS